s6y

BillionToOne, Inc.

Ticker
BLLN
CIK
2070849
Industry
Services-Medical Laboratories

Financials 5

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025

News 9

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing

Ownership 87

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 3 Initial statement of beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 87 ownership filings

Prospectus 9

  1. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. S-1/A General form of registration statement for all companies including face-amount certificate companies
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. DRSLTR Correspondence Related to Draft Registration Statement
  6. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  7. DRSLTR Correspondence Related to Draft Registration Statement
  8. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Proxies 2

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements

Other 69

  1. SCHEDULE 13D/A
  2. 144 Filing for proposed sale of securities under Rule 144
  3. 144 Filing for proposed sale of securities under Rule 144
  4. 144 Filing for proposed sale of securities under Rule 144
  5. 144 Filing for proposed sale of securities under Rule 144
  6. 144 Filing for proposed sale of securities under Rule 144
  7. 144 Filing for proposed sale of securities under Rule 144
  8. 144 Filing for proposed sale of securities under Rule 144
  9. 144 Filing for proposed sale of securities under Rule 144
  10. 144 Filing for proposed sale of securities under Rule 144

All 69 other filings